Skip to Content

Join the 'Humira' group to help and get support from people like you.

Humira News

FDA Approves Humira (adalimumab) for Moderate to Severe Hidradenitis Suppurativa

Posted 11 Sep 2015 by

NORTH CHICAGO, Ill., Sept. 10, 2015 /PRNewswire/ – AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa (HS). Humira is now the first and only FDA-approved therapy for adults with HS. Hidradenitis suppurativa is a chronic inflammatory skin disease characterized by inflamed, painful lesions typically located around the armpits and groin, on the buttocks and under the breasts.1-2 Earlier this year, the FDA granted Humira orphan drug designation for the treatment of moderate to severe HS (Hurley Stage II and Hurley Stage III disease), a population of fewer than 200,000 patients. The orphan drug designation provides Humira the potential to be granted seven years of market exclusivity for the treatment of moderate to severe HS. ... Read more

Related support groups: Humira, Hidradenitis Suppurativa, Humira Pen, Adalimumab

Experimental Psoriasis Drug Shows Promise

Posted 8 Jul 2015 by

WEDNESDAY, July 8, 2015 – Preliminary trial results suggest that an experimental psoriasis drug may control the chronic skin disease better than the current standard treatment. The drug, guselkumab, was compared to the commonly used medication adalimumab (Humira, Enbrel) in a study involving nearly 300 patients with plaque psoriasis. Up to 86 percent of patients who received guselkumab cleared their psoriasis or had minimal psoriasis after 16 weeks of treatment, compared to 58 percent of patients taking adalimumab, the researchers reported. However, patients getting guselkumab were somewhat more prone to infections, the researchers said. "As a dermatologist, I am particularly excited about the potential of guselkumab and what this investigational therapy may mean for patients and the treatment of moderate to severe plaque psoriasis in the future," said lead researcher Dr. Kristian ... Read more

Related support groups: Psoriasis, Humira, Plaque Psoriasis, Adalimumab

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead researcher Dr. Sebastien Viatte, a research fellow at the University of Manchester in England. Using data from several sources on thousands of patients in the United Kingdom, researchers found that gene mutations at a location on a chromosome called HLA-DRBl were associated with rheumatoid arthritis severity and the response to treatment with tumor necrosis factor (TNF) inhibitor drugs. This study, Viatte said, is a potentially important first step toward personalized medicine for patients with the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Imuran, Orencia, Cimzia, Azathioprine, Leflunomide, Arava, Juvenile Rheumatoid Arthritis, Rituximab, Simponi, Otezla, Xeljanz, Infliximab

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – which include drugs such as adalimumab (Humira), anakinra (Kineret) and etanercept (Enbrel) – have allowed patients to gain better control of rheumatoid arthritis when taken early in the course of disease, the researchers explained. But some of the new drugs top $20,000 annually, according to the April 21 online report in the journal Arthritis & Rheumatology. "Many patients face a growing and unacceptable financial burden for access to treatment," said study lead author Dr. Jinoos Yazdany of the ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Imuran, Orencia, Leflunomide, Azathioprine, Arava, Rituximab, Otezla, Xeljanz, Infliximab, Adalimumab, Etanercept, Kineret

Smokers May Get Less Benefit From Drugs for Arthritic Back Pain

Posted 10 Feb 2015 by

TUESDAY, Feb. 10, 2015 – Smoking may hamper the effects of certain drugs used to treat inflammatory arthritis in the lower back, a new study from Switzerland says. Researchers from University Hospital Zurich looked at how 700 people with this type of arthritis responded to treatment with a class of drugs called tumor necrosis factor (TNF) inhibitors. About two-thirds of the patients were smokers. After one to two years of treatment, the drugs were significantly less effective in smokers. The difference was particularly apparent among patients who had higher levels of an inflammatory marker called C-reactive protein at the start of the study. Former smokers did not experience reduced effectiveness from the drugs, according to the study. The research only saw an association between smoking and the drugs' benefits, not a cause-and-effect relationship. The results were published online ... Read more

Related support groups: Back Pain, Rheumatoid Arthritis, Smoking, Humira, Enbrel, Remicade, Cimzia, Simponi, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Certain Autoimmune Drugs in Pregnancy May Up Newborn Infection Risk: Study

Posted 3 Oct 2014 by

FRIDAY, Oct. 3, 2014 – When given to pregnant women, a common treatment for ulcerative colitis may inadvertently lower their baby's ability to fight off infections at birth, new French research suggests. The treatment, called anti-TNF therapy, is an injected, artificial antibody. This type of medication is widely seen as a safe and effective way to tackle a wide range of autoimmune disorders, such as rheumatoid arthritis and inflammatory bowel conditions that include ulcerative colitis and Crohn's disease. It's not unusual for pregnant women to receive the treatment, given that inflammatory bowel diseases often strike women of childbearing age. However, this type of drug can cross the placenta and reach the fetus, the study authors said. And four French cases – all involving babies born to women exposed to Remicade (infliximab) during pregnancy – suggest the therapy may cause newborn ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Crohn's Disease, Remicade, Ulcerative Colitis, Cimzia, Inflammatory Bowel Disease, Simponi, Infliximab, Adalimumab, Etanercept, Certolizumab, Golimumab

FDA Approves Humira (adalimumab) for the Treatment of Pediatric Patients with Crohn's Disease

Posted 26 Sep 2014 by

NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ – AbbVie announced today that the U.S. Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for Humira in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home. "Moderate to severe Crohn's disease is a serious chronic disorder that can impact children and adolescents in significant ways during this important stage of their lives," said Jeffrey S. Hyams, M.D., head, Division of Digestive Diseases, Hepatology and Nutrition, Connecticut Children's Medical Center. "The approval of ... Read more

Related support groups: Humira, Crohn's Disease, Adalimumab

Many Rheumatoid Arthritis Patients May Skip Meds: Study

Posted 3 Sep 2014 by

WEDNESDAY, Sept. 3, 2014 – Many patients with severe rheumatoid arthritis don't take their expensive medications as prescribed, a new British study finds. Failure to take the drugs correctly reduces their effectiveness and may lead to a worsening of symptoms, warned researchers from the University of Manchester. Rheumatoid arthritis develops when your immune system begins to attack itself, and symptoms include inflammation, pain and swelling in the joints and internal organs. The study included 286 patients who had rheumatoid arthritis for seven years and had been prescribed anti-TNF drugs, which cost about $13,000 to $20,000 a year per patient. Anti-TNF drugs include etanercept (Enbrel), adalimumab (Humira) and golimumab (Simponi). Twenty-seven percent of the patients said they didn't take the medications as directed at least once over the first six months after being prescribed the ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Simponi, Adalimumab, Etanercept, Golimumab

Popular Crohn's, Colitis Drugs Not Linked to Short-Term Cancer Risk: Study

Posted 18 Jun 2014 by

WEDNESDAY, June 18, 2014 – A popular class of drugs used to treat inflammatory bowel disease isn't linked to an increase in the short-term risk of cancer, Danish researchers report. Researchers found that people with Crohn's disease or colitis who received the drugs – tumor necrosis factor alpha (TNF-a) antagonists – had about the same risk of cancer as other people with these inflammatory bowel diseases who were not treated with the medication. The drugs work by interrupting the function of TNF-a, a substance used by the immune system to increase inflammation. "Treatment with these drugs inhibits the inflammatory response in the gastrointestinal tract thereby leading to reduced symptoms," said lead author Dr. Nynne Nyboe Andersen of the Statens Serum Institute in Copenhagen. The problem is that TNF-a also serves a key role in protecting the body against cancer, raising concerns that ... Read more

Related support groups: Humira, Enbrel, Crohn's Disease, Remicade, Ulcerative Colitis, Colorectal Cancer, Cimzia, Inflammatory Bowel Disease, Simponi, Infliximab, Adalimumab, Etanercept, Certolizumab, Golimumab

Certain Rheumatoid Arthritis Drugs May Also Protect Patients' Hearts, Studies Find

Posted 27 Oct 2013 by

SATURDAY, Oct. 26 – Drugs that people with rheumatoid arthritis use to help ease the symptoms of the disease might also help ward off heart trouble, two new studies find. Researchers in Sweden found that so-called "biologic" drugs, known as tumor necrosis factor inhibitors, or anti-TNFs, slightly reduce the risk for acute coronary syndrome – a condition that includes angina and heart attack in which blood supply to the heart muscle is suddenly blocked. In another study, British scientists also found taking these drugs was associated with a lower risk for heart attack in patients with rheumatoid arthritis. The findings were to be presented Saturday at the American College of Rheumatology's annual meeting in San Diego. Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal. The roughly 1.3 million Americans affected by the ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Remicade, Cimzia, Simponi, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Rheumatoid Arthritis Treatment May Not Work As Well for Heavier Patients

Posted 18 Jun 2013 by

TUESDAY, June 18 – Overweight and obese people with rheumatoid arthritis are less likely to go into remission in the early stages of the disease and require much more drug treatment than people with normal weight, according to a new study. The study included nearly 350 people with early rheumatoid arthritis (RA) who underwent a treatment meant to achieve remission of their disease. The strategy included strict follow-up visits, as well as treatment with steroids and the drug methotrexate, combined with anti-tumor necrosis factor (anti-TNF) therapy if a good response didn't occur. Anti-TNF drugs are used to reduce inflammation in a variety of conditions. At six and 12 months of follow-up, overweight and obese patients had lower rates of remission. After 12 months, a higher percentage of overweight and obese patients were still on anti-TNF therapy, compared to normal-weight patients. The ... Read more

Related support groups: Obesity, Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Cimzia, Simponi, Infliximab, Adalimumab, Etanercept, Trexall, Certolizumab, Methotrexate LPF Sodium, Golimumab, Folex PFS, Rheumatrex Dose Pack

Many Stop Taking Rheumatoid Arthritis Meds Too Soon: Study

Posted 14 Jun 2013 by

FRIDAY, June 14 – About half of rheumatoid arthritis patients stopped taking their medications within two years after they started them, a new study finds. Rheumatoid arthritis affects about one in 100 people worldwide and can cause progressive joint destruction, deformity, pain and stiffness. The disease can reduce physical function, quality of life and life expectancy. The main reason about one-third of patients discontinued their medications was because the drugs lost their effectiveness, the study authors found. Other reasons included safety concerns (20 percent), doctor preference (nearly 28 percent), patient preference (about 18 percent) and access to treatment (9 percent), according to the study results, which were presented Thursday at the annual meeting of the European League Against Rheumatism (EULAR), in Madrid, Spain. Rheumatoid arthritis "is a progressive disease, which, ... Read more

Related support groups: Rheumatoid Arthritis, Humira, Enbrel, Remicade, Cimzia, Simponi, Infliximab, Adalimumab, Etanercept, Golimumab, Certolizumab

Newer Rheumatoid Arthritis Drugs Don't Seem to Increase Risk of Shingles

Posted 5 Mar 2013 by

TUESDAY, March 5 – The newest medications used to treat autoimmune diseases such as rheumatoid arthritis don't appear to raise the risk of developing shingles, new research indicates. There has been concern that these medications, called anti-tumor necrosis factor (anti-TNF) drugs, might increase the chances of a shingles infection (also known as herpes zoster) because they work by suppressing a part of the immune system that causes the autoimmune attack. "These are commonly used drugs for people with rheumatoid arthritis and other autoimmune diseases, and the issue was whether or not they increased the risk of [shingles]. We found there is no increased risk when using these drugs, which was reassuring," said study author Dr. Kevin Winthrop, associate professor of infectious disease and public health and preventive medicine at Oregon Health and Science University in Portland. Results ... Read more

Related support groups: Rheumatoid Arthritis, Herpes Zoster, Humira, Enbrel, Remicade, Cimzia, Simponi, Infliximab, Adalimumab, Etanercept, Certolizumab, Golimumab

Humira's Approval Widened to Include Ulcerative Colitis

Posted 30 Sep 2012 by

FRIDAY, Sept. 28 – Humira (adalimumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe ulcerative colitis in adults, the agency said Friday. Humira – a type of drug called an anti-tumor necrosis factor that's designed to suppress abnormal inflammatory and immune responses – has already been approved to treat a host of conditions, including rheumatoid arthritis, Crohn's disease and plaque psoriasis. Ulcerative colitis causes inflammation and ulcers in the inner lining of the large intestine. With common symptoms including unusual stool frequency and rectal bleeding, it affects about 620,000 people in the United States, according to the U.S. National Institutes of Health. The most common side effects of Humira include infection, injection-site reaction, headache and rash, according to an FDA news release. The drug is manufactured by Abbott ... Read more

Related support groups: Humira, Ulcerative Colitis, Adalimumab

FDA Approves Humira to Treat Ulcerative Colitis

Posted 28 Sep 2012 by

September 28, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Humira (adalimumab) to include treatment of moderate-to-severe ulcerative colitis in adults. Humira is approved to control ulcerative colitis when immunosuppressant medicines like corticosteroids, azathioprine, and 6-mercaptopurine have not worked. The drug is an anti-tumor necrosis factor (TNF) that blocks proteins that play an important role in abnormal inflammatory and immune responses. Ulcerative colitis is a chronic disease that causes inflammation and ulcers in the inner lining of the large intestine. It is one of two main forms of chronic inflammatory bowel disease and affects about 620,000 Americans, according to the National Institutes of Health. “Each patient with ulcerative colitis experiences the disease differently, and treatment must be adjusted to meet each individual’s nee ... Read more

Related support groups: Humira, Ulcerative Colitis, Humira Pen, Adalimumab

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease - Maintenance, Hidradenitis Suppurativa, Psoriasis, Plaque Psoriasis, Spondyloarthritis, Juvenile Idiopathic Arthritis, Crohn's Disease - Acute

Humira Patient Information at